Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

23 May 2022

Abstract excerpt

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute lymphoblastic leukemia (B-ALL), we report on our phase 1 dose-escalation study of a novel murine stem cell virus (MSCV)-CD19/CD22-4-1BB bivalent CAR T-cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35605184
DOI: 10.1182/blood.2022015795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARPMID 35605184Read ↗

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read ↗

Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALLSemantic proximity Read ↗

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22Semantic proximity Read ↗

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity Read ↗

Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantationSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemiaSemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.